UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000001236
Receipt number R000001508
Scientific Title Phase II study in combination with Carboplatin and TS-1 for Cancer of unknown primary
Date of disclosure of the study information 2008/08/01
Last modified on 2012/01/10 15:45:07

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Phase II study in combination with Carboplatin and TS-1 for Cancer of unknown primary

Acronym

CBDCA/TS-1 for CUP

Scientific Title

Phase II study in combination with Carboplatin and TS-1 for Cancer of unknown primary

Scientific Title:Acronym

CBDCA/TS-1 for CUP

Region

Japan


Condition

Condition

Cancer of unknown primary

Classification by specialty

Medicine in general

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate efficacy in combination with Carboplatin and TS-1 for cancer of unknown primary

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Phase II


Assessment

Primary outcomes

Response rate (RECIST criteria)

Key secondary outcomes

Adverse events (NCI-CTC/AE version 3)


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Carboplatin AUC5 (day1)
TS-1 (P.O.) 40 mg/m-2 BID (day1 - 14)
max 6 cycles or until PD

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

a) Cancer of unknown primary (histologically proven carcinoma, primary site was not detected by systemic survey)
b) Age >= 20 yrs
c) Performance status (ECOG) 0-2
d) Mesurable lesion by the RECIST criteria
e) Adequate organ functions
f) no prior chemotherapy for CUP
g) written informed consent

Key exclusion criteria

a) Specific subgroups of CUP
(female(adenocarcinoma, Ax LN metastases), female (adenocarcinoma, peritonitis carcinomatosa), squamous cell carcinoma of cervical LN metastases, etc.)
b) history of any malignancies
c) massive effusion (thorax or abdominal cavity)
d) symptomatic brain metastases
e) uncontrolled cormobity (DM, hypertension, infection)
f) internal use of phenytoine, flucytosyne, or warfarin

Target sample size

35


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Masashi Ando

Organization

National Cancer Center Hospital, Tokyo

Division name

Dept of Breast and Oncology

Zip code


Address

Tskiji 1-1, 5 Cho-me, Chuo-ku, Tokyo, Japan

TEL

03-3542-2511

Email



Public contact

Name of contact person

1st name
Middle name
Last name Masashi Ando

Organization

National Cancer Center Hospital, Tokyo

Division name

Dept of Breast and Oncology

Zip code


Address


TEL


Homepage URL


Email



Sponsor or person

Institute

National Cancer Center Hospital, Tokyo

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

国立がん研究センター中央病院(東京都)


Other administrative information

Date of disclosure of the study information

2008 Year 08 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Date of protocol fixation

2008 Year 05 Month 16 Day

Date of IRB


Anticipated trial start date

2008 Year 07 Month 01 Day

Last follow-up date

2012 Year 06 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2008 Year 07 Month 09 Day

Last modified on

2012 Year 01 Month 10 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001508


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name